Mild cognitive impairment and dementia

Annual Review of Clinical Psychology

Volumn 2, Issue , 2006, Pages 379-388

  Albert, Marilyn S ^a   Blacker, Deborah ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; APOE; Biomarkers; Clinical trials; MCI

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE; ROFECOXIB;

CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; HUMAN; MEMORY DISORDER; NEUROIMAGING; NEUROPSYCHOLOGY; REVIEW;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COGNITION DISORDERS; DEMENTIA; HUMANS; INDANS; MODELS, PSYCHOLOGICAL; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; SYNDROME; TERMINOLOGY; TREATMENT OUTCOME;

EID: 33744473043     PISSN: 15485943     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.clinpsy.1.102803.144039     Document Type: Review

References (37)

1. Albert M, Moss M. 1996. Neuropsychology of aging: findings in humans and monkeys. In The Handbook of the Biology of Aging, ed. E Schneider, J Rowe, T Johnson, N Holbrook, J Morrison, pp. 217-33. San Diego, CA: Academic
2. Alzheimer A. 1907. Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Zeitschr. Psychiatr. Psychisch-Gerichtl. Med. 64:146-48
3. Am. Psychiatr. Assoc. 1994. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am. Psychiatr. Assoc. Press. 4th ed.
4. Andreason N, Blennow K. 2005. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg. 107:165-73
5. Bennett D, Schneider J, Bienias J, Evans DA, Wilson RS. 2005. Mild cognitive impairment is related to Alzheimer pathology and cerebral infarctions. Neurology 64:834-41
6. Bennett D, Wilson R, Schneider J, Evans DA, Beckett LA, et al. 2002. Natural history of mild cognitive impairment in older persons. Neurology 59:198-205
7. Blacker D, Albert M, Bassett S, Go R, Harrell E, Folstein M. 1994. Reliability and validity of NINCDS-ADRA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch. Neurol. 51: 1198-204
8. Blennow K. 2004. CSF biomarkers for mild cognitive impairment. J. Intern. Med. 256: 224-34
9. Chan D, Janssen J, Whitwell J, Watt H, Jenkins R, et al. 2003. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 362:1121-22
10. Copeland M, Daly E, Hines V, Mastromauro C, Zaitchik D, et al. 2003. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 17:1-8
11. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. 2000. Predicting "conversion" to AD using standardized clinical information. Arch. Neurol. 57:675-80
12. Davis H, Rockwood K. 2004. Conceptualization of mild cognitive impairment: a review. Int. J. Geriatr. Psychiatry 19:313-19
13. Fisk J, Merry H, Rockwood K. 2003. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology 61:1179-84
14. Flicker C, Ferris S, Reisberg B. 1991. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 41:1006-9
15. Fioravanti M, Thorel M, Ramelli L, Napoleoni A. 1985. Reliability between five forms of the Randt Memory Test and their equivalence. Arch. Gerontol. Geriatr. 4:357-64
16. Gauthier S, Touchon J. 2005. Mild cognitive impairment is not a clinical entity and should not be treated. Arch. Neurol. 62:1164-66
17. Hwang T, Masterman D, Ortiz F, Fairbanks L, Cummings J. 2004. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis. Assoc. Disord. 18:17-21
18. Jack C, Petersen R, Xu Y, O'Brien P, Smith G, Ivnik R. 2000. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484-89
19. Johnson K, Jones K, Holman L, Becker A, Spiers P, et al. 1998. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50:1563-71
20. Kantorci K, Jack C, Xu Y, Campeau N, O' Brien P, et al. 2000. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 55:210-17
21. Katzman R. 1976. The prevalence and malignancy of Alzheimer disease. A major killer. Arch. Neurol. 33:217-18
22. Killiany R, Gomez-Isla T, Moss M, Kikinis R, Sandor T, et al. 2000. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol. 47:430-39
23. Larrieu S, Letenneur L, Orgogozo J, Fabrigoule C, Amieva H, et al. 2002. Incidence and outcome of mild cognitive impairment: a population-based prospective cohort. Neurology 59:1594-99
24. McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan E. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force. Neurology 34:939-44
25. Morris J, Storandt M, Miller J, McKeel D, Price J, et al. 2001. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch. Neurol. 58:397-405
26. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, et al. 1997. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 48:1508-10
27. NIA-Reagan Working Group. 1997 Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 18:81-27
28. Petersen R. 2004. Mild cognitive impairment. J. Intern. Med. 256:183-94
29. Petersen R, Dickson D, Parisi J, Johnson R, Ivnik R, Smith G. 2000. Neuropathologic substrate of mild cognitive impairment. Neurobiol. Aging 21:8198
30. Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56:303-8
31. Petersen R, Thomas R, Grundman M, Bennett D, Doody R, et al. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352:2379-88
32. Ritchie K, Artero S, Touchon J. 2001. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 56:37-42
33. Rubin E, Morris J, Grant E, Vendegna T. 1989. Very mild senile dementia of the Alzheimer type. I. Clinical assessment. Arch. Neurol. 46:379-82
34. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, et al. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-72
35. Selkoe D. 2005. Defining molecular targets to prevent Alzheimer disease. Arch. Neurol. 62:192-95
36. Storandt M, Grant M, Miller P, Morris J. 2002. Rates of progression in mild cognitive impairment and early Alzheimer disease. Neurology 59:1034-41
37. Thai L, Ferris S, Kirby L, Block G, Lines C, et al. 2005. A randomized double-blind study of rofecoxib in patients with mild cognitive impairment. Neuropharmacology 30:1204-15